Author(s):
Savulescu, Camelia ; Prats-Uribe, Albert ; Brolin, Kim ; Uusküla, Anneli ; Bergin, Colm ; Fleming, Catherine ; Murri, Rita ; Zvirbulis, Viesturs ; Zavadska, Dace ; Gaio, Vania ; Popescu, Corneliu P. ; Hrisca, Raluca ; Cisneros, Maria ; Latorre-Millán, Miriam ; Lohur, Liis ; McGrath, Jonathan ; Ferguson, Lauren ; De Gaetano Donati, Katleen ; Abolina, Ilze ; Gravele, Dagne ; Machado, Ausenda ; Florescu, Simin-Aysel ; Lazar, Mihaela ; Subirats, Pilar ; Clusa Cuesta, Laura ; Sui, Jacklyn ; Kenny, Claire ; Santangelo, Rosaria ; Krievins, Dainis ; Barzdina, Elza Anna ; Valadas Henriques, Camila ; Kosa, Alma Gabriela ; Pohrib, Saftica-Mariana ; Muñoz-Almagro, Carmen ; Milagro, Ana ; Bacci, Sabrina ; Nardone, Anthony ; VEBIS HCW VE study group ; Collaborators in VEBIS HCW study group
Date: 2024
Persistent ID: http://hdl.handle.net/10400.18/10494
Origin: Repositório Científico do Instituto Nacional de Saúde
Subject(s): COVID-19; SARS-CoV-2; Vaccine effectiveness; Healthcare workers; Europe; Estados de Saúde e de Doença; Observação em Saúde e Vigilância
Description
COVID-19 vaccination recommendations prioritise healthcare workers (HCWs), considering their exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) and their key role in the functioning of healthcare systems. In the European Union/European Economic Area (EU/EEA), HCWs were considered a priority for COVID-19 revaccination during the autumn 2023 campaign [1], and the World Health Organization (WHO) recommended revaccination of HCWs 12 months after their last dose [2]. Because the Omicron sub-lineage XBB.1.5 predominated in spring 2023, the COVID-19 vaccines were adapted to target this emerging strain, and the first XBB.1.5 vaccine was authorised for use in the EU/EEA in August 2023. Omicron BA.2.86/JN.1 emerged in the EU/EEA at the end of 2023, according to data available on the European Respiratory Virus Surveillance Summary (ERVISS) [3]. Evidence for COVID-19 vaccine recommendation in the HCW population remains scarce. Within the Vaccine Effectiveness, Burden and Impact (VEBIS) project, we aimed to measure the COVID-19 vaccine effectiveness (CVE) in HCWs, in the winter season 2023/24.
